These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33849532)

  • 1. Identification of genes and pathways involved in malignant pleural mesothelioma using bioinformatics methods.
    Liu X; Qian K; Lu G; Chen P; Zhang Y
    BMC Med Genomics; 2021 Apr; 14(1):104. PubMed ID: 33849532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis.
    Zhang X; Yang L; Chen W; Kong M
    Oncol Res Treat; 2020; 43(12):656-671. PubMed ID: 33032291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
    Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
    Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
    Mejia-Garcia A; Bonilla DA; Ramirez CM; Escobar-Díaz FA; Combita AL; Forero DA; Orozco C
    Biochem Genet; 2024 Feb; 62(1):352-370. PubMed ID: 37347449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 10. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker.
    Lin P; Zhao Y; Li X; Liang Z
    Comb Chem High Throughput Screen; 2022; 25(9):1498-1506. PubMed ID: 34238152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
    Wright CM; Kirschner MB; Cheng YY; O'Byrne KJ; Gray SG; Schelch K; Hoda MA; Klebe S; McCaughan B; van Zandwijk N; Reid G
    PLoS One; 2013; 8(8):e70940. PubMed ID: 23976967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
    Vavougios GD; Solenov EI; Hatzoglou C; Baturina GS; Katkova LE; Molyvdas PA; Gourgoulianis KI; Zarogiannis SG
    Am J Physiol Lung Cell Mol Physiol; 2015 Oct; 309(7):L677-86. PubMed ID: 26254420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
    Xiao Y; Huang W; Zhang L; Wang H
    Front Endocrinol (Lausanne); 2022; 13():1056152. PubMed ID: 36523602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
    Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.